DrugPatentWatch Database Preview
Therapeuticsmd Inc Company Profile
What is the competitive landscape for THERAPEUTICSMD INC, and what generic alternatives to THERAPEUTICSMD INC drugs are available?
THERAPEUTICSMD INC has one approved drug.
There are two US patents protecting THERAPEUTICSMD INC drugs.
There are seventy-eight patent family members on THERAPEUTICSMD INC drugs in twelve countries and twenty-seven supplementary protection certificates in eleven countries.
Summary for Therapeuticsmd Inc
| International Patents: | 78 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Therapeuticsmd Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeuticsmd Inc | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Therapeuticsmd Inc | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | RX | Yes | Yes | 9,180,091 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Therapeuticsmd Inc | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | RX | Yes | Yes | 9,289,382 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Therapeuticsmd Inc | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Therapeuticsmd Inc | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | RX | Yes | No | 9,180,091 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Therapeuticsmd Inc | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | RX | Yes | No | 9,289,382 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Therapeuticsmd Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,987,238 | Natural combination hormone replacement formulations and therapies | ➤ Sign Up |
| D801518 | Pharmaceutical capsule | ➤ Sign Up |
| 8,633,178 | Natural combination hormone replacement formulations and therapies | ➤ Sign Up |
| 9,301,920 | Natural combination hormone replacement formulations and therapies | ➤ Sign Up |
| 8,993,548 | Natural combination hormone replacement formulations and therapies | ➤ Sign Up |
| 9,114,145 | Natural combination hormone replacement formulations and therapies | ➤ Sign Up |
| 8,846,649 | Natural combination hormone replacement formulations and therapies | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Therapeuticsmd Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013078422 | ➤ Sign Up |
| Canada | 2876947 | ➤ Sign Up |
| Japan | 2015520235 | ➤ Sign Up |
| Argentina | 098160 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2013192249 | ➤ Sign Up |
| European Patent Office | 3060179 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2017100378 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Therapeuticsmd Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00C/027 | Belgium | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| 2009 00017 | Denmark | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| C0004 | Belgium | ➤ Sign Up | PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306 |
| 156 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| C/GB04/032 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 |
| 09/012 | Ireland | ➤ Sign Up | PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
